MARGIN: Evaluation of the Efficacy of Two Guidance Techniques (Standard Injected CT vs Porto-scanner With Angio-CT) for Thermoablation Treatment of Colorectal Cancer Liver Metastases
Study Details
Study Description
Brief Summary
Hepatic metastases of colorectal cancer (CRC) are partially necrotic tumors mainly vascularized by the hepatic artery. When resectable, these metastases must be removed with a safety margin of 1 mm. Resection margins greater than 1 cm are associated with better disease-free survival and no local recurrence. Thermoablation systems allow for ablation zones of approximately 4.5-5 cm in diameter. For tumors <3 cm, subject to perfect targeting, it is possible to obtain ablation margins of 1 cm, which would greatly reduce the local recurrence rate. Accurate assessment of these tumor boundaries and characterization of these margins are paramount to ensure complete ablation.
Thermoablation for these small liver metastases (<3cm) has shown equivalent efficacy to surgery in terms of recurrence and survival with fewer complications. Thermoablation treatment is indicated for patients with stable disease undergoing chemotherapy. This leads to liver remodeling and metastases become difficult to see on ultrasound and CT scans. The study authors hypothesize that the porto-scanner guidance technique with Angio-CT for thermoablation treatment of CRC liver metastases will allow a better exploration of these metastases by allowing a better identification of the margins and thus ensure a more accurate and complete treatment for patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Control
|
Procedure: Thermoablation with standard CT guidance
Guidance with small volume breathing and high frequency. The contrast product will be venously injected in the elbow.
|
| Experimental: Porto-scanner guidance with Angio-CT
|
Procedure: Thermoablation with porto-scanner guidance with Angio-CT
Real time guidance, small volume and high frequency respiration. Contrast medium will be directly injected into the superior mesenteric artery (SMA) after puncture of the femoral artery at the inguinal fold and catheterization of the SMA.
|
Outcome Measures
Primary Outcome Measures
- Efficacy of conventional CT versus porto-scanner for thermoablation of colorectal cancer liver metastases between groups [3 months]
Percentage, where complete response is defined as complete ablation of the treated lesions (complete disappearance of enhancement and hypermetabolism) with no new lesions appearing, determined on imaging.
Secondary Outcome Measures
- Difference in response rate per lesion between the groups [3 months]
Percentage
- Difference in distant recurrences between the groups [12 Months]
- Difference in local recurrences between the groups [12 Months]
Yes/no presence of recurrence
- Recurrence free survival between the groups [12 months]
Days
- Local recurrence-free survival between the groups [12 months]
Days
- Distant recurrence-free survival between the groups [12 months]
Days
- Difference in time until recurrence between the groups [12 months]
Days
- Size of the lesions [3 months]
mm
- Diameter of the tumor in axial [3 months]
mm
- Location of the lesions [3 months]
Dome/left liver/sub capsular/contact with a large vessel (> 5mm)
- Size of the ablation area [3 months]
mm
- Feasibility of porto-scanner [End of procedure (Day 0)]
Presence of metastatic lesions by scanner yes/no
- Complications arising during intervention [End of procedure (Day 0) until 3 months]
Complications related to the approach (vascular complications), related to the percutaneous procedure (hematoma, active bleeding) or related to the treatment; Clavien-Dindo classification
- Reason for for failure of technique requiring switch to different guidance technique [End of procedure (Day 0)]
Vascular problem (failure of catheterization) or problem of elevation (no optimal elevation of the liver allowing guidance)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
The patient must have given their free and informed consent and signed the consent form
-
The patient must be a member or beneficiary of a health insurance plan
-
Patients with CRC liver metastases (< 3 lesions, < 3 cm in diameter), proven on MRI and/or Positron Emission Tomography scan.
-
Patient eligible for thermoablation requiring CT guidance (at least one metastasis not visible on ultrasound).
-
Treatment by thermoablation validated in multidisciplinary meeting.
-
Eastern Cooperative Oncology Group performance score 0-2.
-
ASA score 1-3.
-
Life expectancy of more than 3 months.
-
Renal function allowing iodinated contrast injection (clearance > 30 mL/min), normal liver function (bilirubin < 35 µmol/L) and hemostasis assessment allowing percutaneous procedure (PT > 50%, platelets > 50 G/L, anticoagulant treatment to be stopped).
-
Postmenopausal patient or patient with effective contraception (hormonal or mechanical)
-
Pregnancy test (bHCG blood) negative in the month prior to inclusion for patients of childbearing age.
Exclusion Criteria:
-
The subject is participating in a category 1 interventional study, or is in a period of exclusion determined by a previous study
-
The subject refuses to sign the consent
-
It is impossible to give the subject informed information
-
The patient is under safeguard of justice or state guardianship
-
Lesion not eligible for thermoablation (proximity of the liver hilum and the main bile duct).
-
Uncorrectable abnormalities of liver or blood functions (coagulation).
-
Severe allergy to contrast media.
-
Contraindication to MRI (pacemaker, neuro-stimulator, cochlear implant, metallic heart valve, claustrophobia).
-
Uncontrolled infection.
-
Any physical, physiological or psychological condition incompatible with study participation or patient compliance.
-
Pregnant, parturient or nursing patient.
-
Contraindications mentioned in the Product Monographs of the following drugs:
-
FLUCIS: Hypersensitivity to the active substance (fludeoxyglucose (18F)) or to one of the excipients.
-
VISIPAQUE 320
-
Hypersensitivity to the active substance or to any of the excipients mentioned in section 6.1.
-
History of immediate major or delayed cutaneous reaction (see section 4.8) to the injection of iodinated contrast material (Visipaque),
-
Decompensated cardiac insufficiency with systemic injection (only concerns high osmolarity ionic products),
-
Overt thyreotoxicosis,
-
Hysterosalpingography in pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | CHU de Montpellier | Montpellier | France | ||
| 2 | CHU de Nîmes | Nîmes | France |
Sponsors and Collaborators
- Centre Hospitalier Universitaire de Nīmes
Investigators
- Principal Investigator: Julien Frandon, CHU de Nimes
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AOI/2020/2021/JF-01